100487-81-8

Basic information

• Product Name: Propanedioic acid, (4-broMo-2-nitrophenyl)-, diMethyl ester
• Synonyms: Propanedioic acid, (4-broMo-2-nitrophenyl)-, diMethyl ester;Propanedioic acid, 2-(4-broMo-2-nitrophenyl)-, 1,3-diMethyl ester;dimethyl 2-(4-bromo-2-nitrophenyl)malonate;1,3-Dimethyl 2-(4-bromo-2-nitrophenyl)propanedioate
• CAS NO: 100487-81-8
• Molecular Formula: C₁₁H₁₀BrNO₆
• Molecular Weight: 332.1042
• Mol File: 100487-81-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Propanedioic acid, (4-broMo-2-nitrophenyl)-, diMethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, (4-broMo-2-nitrophenyl)-, diMethyl ester(100487-81-8)
• EPA Substance Registry System: Propanedioic acid, (4-broMo-2-nitrophenyl)-, diMethyl ester(100487-81-8)

Safety Data

• Hazardous Substances Data: 100487-81-8(Hazardous Substances Data)

Upstream product

• 3460-18-2 1,4-dibromo-2-nitrobenzene 
• 108-59-8 malonic acid dimethyl ester 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 

Downstream Products

• 99365-40-9 6-bromo-2,3-dihydro-1H-indole-2-one 
• 1098855-11-8 C₉H₆BrNO₆ 
• 893441-85-5 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline-2-one 
• 1202772-48-2 methyl 2-(4-bromo-2-nitrophenyl)-2-hydroxy-3-((2-hydroxyethyl)(methyl)amino)propanoate 
• 1202765-56-7 6-bromo-2',3',5',6'-tetrahydrospiro[dihydroindole-3,4'-pyran] 
• 1202765-72-7 methyl 2-(4-bromo-2-nitrophenyl)oxirane-2-carboxylate 
• 1190861-43-8 6-bromo-2',3',5',6'-tetrahydrospiro[indoline-3,4'-pyran]-2-one 
• 90725-50-1 (3-RS)-6-bromo-2,3-dihydro-3-methyl-1H-indole-2-one 
• 6127-11-3 (4-bromo-2-nitrophenyl)acetic acid 
• 848649-94-5 6-bromoindoline-2-thione 
• 100487-82-9 4-bromo-2-nitro-benzoic acid methyl ester 
• 1202765-70-5 methyl 2-(4-bromo-2-nitrophenyl)acrylate 
• 1291104-18-1 (4S,5R)-2,2-diethyl 4-methyl 4-(4-bromo-2-nitrophenyl)-5-phenylpyrrolidine-2,2,4-tricarboxylate 
• 1202764-93-9 dimethyl 2-(4-bromo-2-nitrophenyl)-2-methylmalonate 

Relevant articles and documents

PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS

The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.

8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS

Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus

TRIAZOLOPYRAZINE DERIVATIVES

Compounds of the formula (I) in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

Iron(II) bromide-catalyzed intramolecular c-h bond amination [1,2]-shift tandem reactions of aryl azides

Iron(II) bromide catalyzes the transformation of ortho-substituted aryl azides into 2,3-disubstituted indoles through a tandem ethereal C-H bond amination [1,2]-shift reaction. The preference for the 1,2-shift component of the tandem reaction was established to be Me 1 2 Ph.

Asymmetic organocatalytic 1,3-dipolar cycloaddition of azomethine ylide to methyl 2-(2-nitrophenyl)acrylate for the synthesis of diastereoisomers of spirotryprostatin A

Chemical equations presented. The total synthesis of two diastereomers of spirotryprostatin A has been established starting with an asymmetric 1,3-dipolar cycloaddition of methyl 2-(2-nitrophenyl)acrylate with azomethine ylides catalyzed by a Bronsted aci

Synthesis of selenophene derivatives as novel CHK1 inhibitors

A series of selenophene derivatives 3 were synthesized as potential CHK1 inhibitors. The effects of substitution on the 4′- or 5′-position of selenophene moiety and shifting the hydroxyl group position on C6- phenolic ring of oxindole were explored. This

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

PROTEIN KINASE INHIBITORS

This invention relates to selenophene compounds of formula (I) shown below: Each variable in formula (I) is defined in the specification. These compounds can be used to treat cancer.

PROTEIN KINASE INHIBITORS

This invention relates to selenophene compounds of formula (I) shown below; each variable in formula (I) is defined in the specification. These compounds can be used to treat cancer.